• Novo Nordisk’s US BLA review for hemophilia A drug denecimig remains ongoing, with no new FDA decision timeline provided.
• Extended review tied to remediation work at a manufacturing facility identified during a pre-license inspection.
• FDA flagged no deficiencies in denecimig clinical efficacy or safety data submitted in the application.
• 2026 financial outlook unchanged; Novo targets a US launch in the first half of 2027, pending FDA action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610021653OMX_____CNEWS_EN_GNW1001276047_en) on October 02, 2026, and is solely responsible for the information contained therein.